Security key
320703507
Calidi Biotherapeutics, Inc. - Common stock, par value $0.0001 per share (CLDI)
CUSIP: 320703507
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Common stock, par value $0.0001 per share
- Total 13F shares
- 223
- Total 13F value
- $239
- Share change
- +223
- SEC-reported price per share
- $1.12
- Number of holders
- 2
- Value change
- +$239
- Number of buys
- 2
- Shares outstanding
- 1,270,361
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
2
Top holders
2
CLDI full security history
Ownership snapshot
Full 13F holder table
Calidi Biotherapeutics, Inc. SEC filings
Calidi Biotherapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 320703507
Recent filing periods:
Ownership snapshot
Top reported holders of CLDI - Calidi Biotherapeutics, Inc. - Common stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Polar Asset Management Pa...
Comparable rows
2/15
Latest evidence
17 Aug 2026
13D/G
3/4/5
Lead comparable stake: 5%
13 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 2
ARMISTICE CAPITAL, LLC
5%
Gavrilov Ognian Anguelov
0.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
Reported 13D/G
· 30 Jun 2026
|
—
63,391 shares
|
$0 | 30 Jun 2026 |
| Gavrilov Ognian Anguelov |
13D/G
|
0.3%
Reported 13D/G
· 31 Mar 2026
|
$6,600
20,000 shares
|
-$224,400 | 31 Mar 2026 |
| Polar Asset Management Partners Inc. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,330,272
412,800 shares
|
— | 19 Oct 2022 |
| Lincoln Alternative Strategies LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$430,700
730,000 shares
|
— | 20 Aug 2025 |
| First Light Acquisition Group, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
1,931,852 shares
|
— | 16 Jun 2023 |
| Stephen Thesing |
3/4/5
Chief Business Officer
|
—
denominator unverified
|
$848,779
471,544 shares
|
— | 12 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
223
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
0
Q3 2026 holders
2
Holder diff
2
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend